In our last analysis , following a stock derating, we decided to reinstate a buy rating on Stevanato Group (NYSE: STVN ). For our new readers, the company is a leading player in drug containment and delivery. Life sciences and biopharmaceutical players useBuy-side hedge professionals conducting fundamental, income oriented, long term analysis across sectors globally in developed markets. Please shoot us a message or leave a comment to discuss ideas.DISCLOSURE: All of our articles are a matter of opinion, in ...